Boehringer Ingelheim v. Sun Pharmaceutical: SYNJARDY XR Consent Judgment After 1,604 Days
Boehringer Ingelheim secured a consent judgment across 11 patents covering SYNJARDY XR (empagliflozin/metformin extended-release tablets) after Sun Pharmaceutical filed ANDAs seeking to launch a generic version. The Delaware District Court entered an injunction barring Sun from commercialising the ANDA products until all 11 patents expire, across a sprawling multi-case consolidation spanning more than four years.
SYNJARDY XR: Multi-patent ANDA battle ends in sweeping consent judgment
Boehringer Ingelheim Corporation and Boehringer Ingelheim International GmbH filed suit in the District of Delaware on 9 March 2021 against Sun Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Inc., and Ohm Laboratories Inc., asserting infringement of multiple patents covering SYNJARDY XR — the brand-name empagliflozin/metformin hydrochloride extended-release combination tablet indicated for type 2 diabetes. The action arose from Sun’s submission of ANDA Nos. 212343, 212339, 214843, 215873, and 215529 seeking FDA approval to market generic versions of SYNJARDY XR in 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg dosage strengths.
The case closed on 30 July 2025 through a consent judgment entered by Judge Colm F. Connolly. The court found all 11 asserted patents — the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents — valid, enforceable, and infringed by Sun’s ANDA products. Sun is permanently enjoined from making, using, selling, offering for sale, importing, or distributing those products in the United States until each patent expires, including any patent term extensions, adjustments, or pediatric exclusivity periods. All remaining claims across seven consolidated civil actions were dismissed without prejudice and without costs to either party.
The 1,604-day duration is consistent with the complexity of multi-case ANDA consolidations in Delaware and the breadth of the patent portfolio asserted — spanning formulation, composition, and method patents. The absence of a costs award and dismissal without prejudice on counterclaims suggests a negotiated resolution preserving some litigation optionality for Sun in connection with non-ANDA products, though the public record does not disclose the commercial terms, if any, underlying the consent arrangement. What remains unknown is whether any licensing arrangement or market-entry date agreement was reached between the parties.
Filing to Consent Judgment in 1604 days
1,604 days — above average for ANDA patent cases in D. Del., reflecting multi-case consolidation
Consent judgment entered: what the ruling means for both parties
Consent judgment — agreed infringement finding with injunctive relief
A consent judgment is a court-entered order reflecting terms agreed by both parties. Here, Sun agreed that all 11 patents are valid, enforceable, and infringed by its ANDA products, and accepted a permanent injunction. The underlying ANDA claims were dismissed without prejudice, meaning Sun retains the theoretical right to challenge these patents in a different context — for example, for a product not covered by the five listed ANDAs — but cannot market a generic SYNJARDY XR until all patents expire.
Agreed infringement + permanent injunctionBoehringer secures full exclusivity through patent expiry across all dosage strengths
The consent judgment delivers Boehringer Ingelheim its preferred commercial outcome: a court-enforced barrier preventing Sun from launching any ANDA product for SYNJARDY XR across all four dosage strengths until the last of the 11 patents — including any extensions or pediatric exclusivity — expires. The judgment also preserves Boehringer’s ability to apply to court if additional regulatory exclusivities are obtained. No costs were awarded, suggesting a clean commercial resolution rather than an adversarial finding.
Full exclusivity preservedSun blocked on all five ANDAs; retains narrow rights for non-ANDA product challenges
Sun Pharmaceutical agreed to be enjoined across all five ANDA numbers and all dosage strengths, effectively conceding the SYNJARDY XR generic market to Boehringer for the patent term. Critically, the consent judgment explicitly carves out Sun’s right to challenge the 11 patents in connection with products not described in those ANDAs. This carve-out suggests the settlement was structured to preserve Sun’s optionality for future reformulations or different product configurations while closing off the immediate ANDA pathway.
Enjoined on all ANDAs; narrow carve-out retained11-patent wall around empagliflozin/metformin ER raises barrier for all generic entrants
The consent judgment effectively validates Boehringer’s layered IP strategy around SYNJARDY XR — stacking formulation, composition, and method patents to create overlapping exclusivity extending well beyond any single patent. For other generic manufacturers holding or contemplating ANDAs for empagliflozin/metformin ER products, this outcome signals that Boehringer will enforce this portfolio aggressively and that a negotiated consent structure, rather than a full trial, may be the realistic resolution. FTO analyses for empagliflozin combination products should account for all 11 patents and their extension periods.
Layered portfolio strategy validatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | Pharmaceutical innovator — holder of SYNJARDY XR empagliflozin/metformin ER patent portfolioSearch in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim Corporation | Company | Search in Eureka ↗ |
| Co-Plaintiff | Boehringer Ingelheim International, GMBH | Company | Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries Limited | Company | Indian generic pharmaceutical manufacturer seeking U.S. ANDA approval for empagliflozin/metformin ER tabletsSearch in Eureka ↗ |
| Co-Defendant | Sun Pharmaceutical Industries, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Ohm Laboratories, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Defendant counsel | Bryce A. Cooper | Attorney | Counsel for Sun Pharmaceutical Industries LimitedSearch in Eureka ↗ |
| Defendant counsel | Charles B. Klein | Attorney | Counsel for Sun Pharmaceutical Industries LimitedSearch in Eureka ↗ |
| Defendant counsel | David A. Bilson | Attorney | Counsel for Sun Pharmaceutical Industries LimitedSearch in Eureka ↗ |
| Defendant counsel | John C. Phillips , Jr. | Attorney | Counsel for Sun Pharmaceutical Industries LimitedSearch in Eureka ↗ |
| Defendant counsel | Michael A. Meneghini | Attorney | Counsel for Sun Pharmaceutical Industries LimitedSearch in Eureka ↗ |
| Defendant law firm | Phillips, McLaughlin & Hall PA | Law Firm | Representing Sun Pharmaceutical Industries LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment is a negotiated court order rather than a contested ruling, meaning the findings of validity, enforceability, and infringement reflect Sun’s agreement rather than an adjudicated determination. The explicit carve-out preserving Sun’s right to challenge the patents for non-ANDA products is a notable drafting feature — it signals that Sun did not make a blanket concession of invalidity. The injunction running through all patent term extensions and pediatric exclusivity means the effective market exclusion period for Sun’s ANDA products is tied to the last-expiring protection across the 11-patent family, making the commercial timeline difficult to model without independent patent expiry analysis.
US9949998B2 — empagliflozin/metformin ER formulation and 3 further patents
The four identified patents — US9949998B2 (app. US14/918727), US10596120B2 (app. US15/906414), US7579449B2 (app. US11/080150), and US10258637B2 (app. US15/918401) — form part of Boehringer Ingelheim’s layered IP estate around SYNJARDY XR. The portfolio spans SGLT2 inhibitor compound claims, pharmaceutical composition claims for empagliflozin/metformin combinations, and extended-release formulation methods. The application dates range from the mid-2000s through to the late 2010s, reflecting successive layers of patent protection built around both the active ingredient and the specific extended-release delivery technology.
For competitors in the SGLT2 inhibitor and type 2 diabetes combination therapy market, this patent family represents a significant FTO challenge. The breadth of the 11-patent portfolio asserted — only four of which are identified in the case data — suggests Boehringer has constructed overlapping claims covering the compound, its formulations, manufacturing processes, and methods of use. Any generic manufacturer considering an ANDA for an empagliflozin-containing combination product, or any innovator developing a competing SGLT2 inhibitor ER combination, should conduct a thorough landscape analysis of the full Boehringer Ingelheim empagliflozin portfolio before committing R&D resources.
Should you run an FTO against US9949998B2 and the SYNJARDY XR patent family?
Any pharmaceutical company, generic manufacturer, or drug delivery technology firm working on SGLT2 inhibitor combination products — particularly empagliflozin or metformin extended-release dosage forms — should treat this case as a direct trigger for FTO analysis. The consent judgment validates all 11 patents as enforceable, and the injunction extends through any patent term adjustments and pediatric exclusivity. R&D teams developing competing ER combinations or reformulations should not assume that design-arounds targeting a single patent are sufficient given the portfolio depth demonstrated here.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map the full Boehringer Ingelheim empagliflozin/metformin patent landscape in minutes — identifying claim scope across all asserted and related patents, expiry timelines including PTE and pediatric exclusivity projections, and white-space opportunities for differentiated formulations. Upload your compound or formulation specification and Eureka will generate a prioritised claim-by-claim risk matrix, flagging which of the 11 consent judgment patents pose the highest barrier to your specific product configuration.
Run a freedom-to-operate analysis on US9949998B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: SGLT2 inhibitor and diabetes combination drug litigation
Explore related ANDA infringement actions in the Delaware District Court involving SGLT2 inhibitor and metformin combination drug patents — the same technology domain and venue as this case.
Related patent case — similar technology
Comparable case in the same technology domain. Patent holder and defendant reached resolution after proceedings.
SettledRelated infringement action — same court
Comparable SYNJARDY XR® (empagliflozin/metformin extended-release) tablets s, for oral use, in 5 mg/1000 mg,10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg dosages-adjacent infringement action. Patent enforcement dynamics analysed in depth.
Active · District CourtRelated invalidity challenge — appellate outcome
Combined invalidity and infringement action in the same technology space. Decided after substantive proceedings.
DecidedBoehringer-Ingelheim’s broader IP enforcement history
Boehringer-Ingelheim’s full litigation history covering prior enforcement, licensing activity, and inter partes review proceedings.
Portfolio viewWhat this case signals for the SGLT2 inhibitor combination drug IP landscape
A 1,604-day multi-case consolidation ending in a 11-patent consent judgment sets a clear enforcement template for branded ANDA defence in Delaware.
Portfolio stacking in ANDA defence: 11 patents create durable exclusivity
Boehringer’s strategy of asserting 11 patents across formulation, composition, and method claims forced Sun into a consent structure rather than a viable invalidity defence. Generic manufacturers entering empagliflozin or SGLT2 combination drug markets should conduct deep FTO reviews covering the full Boehringer portfolio — not just the lead compound patents — before filing ANDAs.
Delaware District Court remains the dominant venue for multi-ANDA pharmaceutical consolidations
Seven consolidated civil actions resolved in a single consent judgment illustrates the efficiency — and risk concentration — of D. Del. ANDA consolidations before Judge Connolly. Defendants facing multi-case consolidation in Delaware should assess early whether a negotiated resolution preserving carve-out rights, as Sun obtained here, is preferable to extended litigation against a deep patent portfolio.
Pediatric exclusivity and PTE clauses in consent judgments: a hidden timeline risk
The consent judgment explicitly extends Sun’s injunction through any patent term extensions, adjustments, and pediatric exclusivity periods. For generics modelling market-entry timelines, this clause means the effective exclusivity period may exceed the statutory patent term by up to 30 months — a material commercial planning consideration that is often underestimated in ANDA strategy.
The ‘non-ANDA product’ carve-out: Sun’s preserved optionality and what it signals
Sun negotiated an explicit right to challenge all 11 patents in connection with products not covered by the five ANDAs. This carve-out, unusual in its specificity, suggests Sun may be developing a reformulated or differently-characterised empagliflozin/metformin product. Competitors and brand holders should monitor Sun’s pipeline filings and any future IPR petitions against this patent family.
Boehringer-Ingelheim v Sun — key questions answered
The Delaware District Court entered a consent judgment on 30 July 2025 finding all 11 asserted patents — including the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents — valid, enforceable, and infringed by Sun’s ANDA products for empagliflozin/metformin hydrochloride extended-release tablets. Sun was permanently enjoined from commercialising those ANDA products until all 11 patents, including any term extensions and pediatric exclusivity, expire.
The case involved five Sun Pharmaceutical ANDAs — Nos. 212343, 212339, 214843, 215873, and 215529 — seeking FDA approval to market generic empagliflozin/metformin hydrochloride extended-release tablets in 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg dosage strengths, corresponding to all commercially available strengths of SYNJARDY XR.
Yes, with limitations. The consent judgment explicitly preserves Sun’s right to challenge the validity, enforceability, and infringement of all 11 patents in connection with a product other than a product described in the five listed ANDAs. Sun is therefore not barred from future IPR petitions or litigation involving different products, but cannot contest these patents in connection with the specific ANDA products covered by the judgment.
Seven civil actions filed in the District of Delaware were consolidated and resolved by the consent judgment: Case Nos. 18-1765, 19-1500, 18-1689, 20-1153, 20-1585, 21-356, 21-1487, 21-1573, and 21-1485. All remaining claims, counterclaims, and affirmative defenses across these actions were dismissed without prejudice and without costs to any party.
Four patents are specifically identified in the case record: US9949998B2 (application US14/918727), US10596120B2 (application US15/906414), US7579449B2 (application US11/080150), and US10258637B2 (application US15/918401). The consent judgment references 11 patents in total — the ‘938, ‘957, ‘998, ‘637, ‘705, ‘016, ‘379, ‘172, ‘120, ‘449, and ‘323 patents — covering SGLT2 inhibitor compositions, empagliflozin/metformin formulations, and extended-release delivery methods.
Track empagliflozin patent expiry and ANDA risk with PatSnap Eureka
With 11 patents and multiple term extensions at play, knowing when SYNJARDY XR generic entry becomes viable is complex. PatSnap Eureka maps expiry timelines, PTE status, and litigation risk across the full Boehringer empagliflozin portfolio.
PatSnap Eureka searches patents and litigation data to answer instantly.